Sum m a r y
The simultaneous occurrence of psoriasis driven by type 1 helper T (Th1) cells and type 17 helper T (Th17) cells and atopic eczema dominated by type 2 helper T (Th2) cells is rare. Here, we describe three patients with co-occurring psoriasis and atopic eczema with an antagonistic course and distinct T-cell infiltrates in lesions from psoriasis and those from atopic eczema. Sensitized patients with psoriasis had a reaction to epicutaneous allergen challenge, with clinically and histologically verified eczema lesions containing a large number of allergen-reactive T cells. These findings support a causative role for T cells triggered by specific antigens in both psoriasis and atopic eczema. (Supported by the German Research Foundation and others.) P soriasis and atopic eczema are prevalent, influence healthrelated quality of life, are associated with concomitant illness, and pose an economic burden. Whether these diseases are epithelial or immunologic disorders is debated. Both involve complex interactions of hereditary factors and environmental influences. Besides altering the skin barrier, these conditions lead to a systemic T-cell-driven immune response with primary involvement of not only the skin but also other sites such as joints (in psoriatic arthritis) or airways (in asthma and rhinitis). Whereas atopic eczema arises from a systemic Th2-cell-dominated immune shift characterized by frequent elevations of total and allergen-specific IgE levels, 1 psoriasis is caused by an immune response driven by Th1 cells, which secrete high levels of interferon-γ, and by Th17 cells, which secrete high levels of interleukin-17A, interleukin-17F, and interleukin-22. 2 In view of their opposing immune mechanisms, one would expect these diseases to be mutually exclusive. Indeed, cases of concomitant psoriasis and atopic eczema are rare. 3 
ME THODS
We evaluated three patients with concomitant psoriasis and atopic eczema and an additional five patients with psoriasis and allergic contact dermatitis to nickel. Diagnoses were made on the basis of clinical presentation, personal history, laboratory findings, and the results of epicutaneous patch testing. In addition, genomic DNA was extracted from leukocyte specimens obtained from the patients and tested for HLA-Cw6 alleles as well as the four most common filaggrin polymorphisms (R501X, T h e n e w e ng l a n d j o u r na l o f m e dic i n e n engl j med 365;3 nejm.org july 21, 2011 232 2282del4, R2447X, and S3247X), as described previously. 4, 5 The clinical presentation of the patients was evaluated by means of the psoriasis area-andseverity index (PASI) and the Scoring Atopic Dermatitis (SCORAD) index. (For details of these grading schemes, see the Supplementary Appendix, available with the full text of this article at NEJM .org.) An epicutaneous challenge to nickel and atopy patch testing of Dermatophagoides pteronyssinus were performed according to standardized protocols. 6, 7 The study was approved by the local ethics committee, and all patients provided written informed consent.
From each patient, punch-biopsy specimens were obtained simultaneously from eczema and psoriasis lesions while the involved areas were under local anesthesia. Biopsy specimens were immediately divided into two parts. One part was fixed in paraformaldehyde for histologic analysis; from the other part, T-cell lines were isolated and further investigated in vitro, as described previously. 8 The cytokine profile of T-cell lines was determined after stimulation with phorbol myristate acetate-ionomycin for 6 hours in the presence of brefeldin A, and intracellular cytokine accumulation was measured by means of three-color flow cytometry, as described previously. 9, 10 In addition, T-cell lines were stimulated with anti-CD3 and anti-CD28 antibody for 72 hours, and secretion of interferon-γ, interleukin-4, interleukin-17, and interleukin-22 levels was quantified by means of commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems).
T-cell specificity was investigated in coculture systems of 10 5 T cells with 3×10 4 autologous monocytes and 5 μg of natural D. pteronyssinus per milliliter (in Patients 1, 2, and 3) or 20 μg of nickel sulfate per milliliter (in Patients 4 through 8), as described previously. 8 Two methods were used: the carboxyfluorescein succinimidyl ester diacetate (CFSE-DA) assay and the thymidine-incorporation method. In the former, T cells were marked with 0.5 μM of the fluorescent dye CFSE-DA and subsequently cocultured as described above. (CFSE-DA stains cells and is divided between them after cell division; a decline in CFSE-DA expression reflects T-cell proliferation.) After 5 days, T cells were also stained with CD69 (a marker of activated T cells), and fluorescence intensity was measured by flow cytometry. In the latter method, T cells were cocultured for 72 hours as described above. Cellfree supernatant was obtained for quantification of cytokine secretion by means of ELISA, and subsequently 10 μg per milliliter of 3 H-thymidine was added to the coculture for an additional 12 hours. Thymidine incorporation was measured by means of a beta-counting device, as described previously. 8 Results are expressed as the proliferation index (i.e., the counts per minute for stimulated T cells divided by the counts per minute for the negative controls).
R E SULT S
Characteristics of the three patients with concomitant psoriasis and atopic eczema are shown in Table 1 and Figure 1 . Although the clinical courses of psoriasis and atopic eczema rarely overlapped, indicating independent regulation of the two immune phenotypes, all three patients had periods with active lesions of both diseases. During such periods, skin-biopsy specimens were obtained from psoriasis lesions and atopic eczema lesions at the same time. Histologic analysis of the specimens showed typical features of each disease, such as acanthosis, elongated rete ridges, and neutrophilic microabscesses in psoriasis lesions and spongiosis as well as a mixed infiltrate of T cells, eosinophils, and granulocytes in atopic eczema lesions ( Fig. 1A) .
Parallel occurrence of antagonistic inflammatory skin reactions may require distinct antigen triggers. In all our patients, the T cells derived from psoriasis lesions and those derived from atopic eczema lesions differed in their cytokine profile. Psoriasis lesions contained a large number of Th1 and Th17 cells, whereas atopic eczema lesions have higher amounts of Th2 and Th22 cells ( Fig. 1A and 2A ). 11, 12 Accordingly, secretion of the Th1 and Th17 cytokines interferon-γ and interleukin-17 was greater in psoriasis-derived T-cell lines, whereas T cells from atopic eczema lesions secreted greater amounts of interleukin-4 in vitro. Interleukin-22 is produced by both Th17 and Th22 cells and was released in similar amounts in the psoriasis lesions and atopic eczema lesions ( Fig. 1D and 2C ).
Psoriasis lesions regularly develop after mechanical trauma or skin irritation (Koebner's phenomenon). 13 To evaluate whether nonspecific responses such as Koebner's phenomenon or antigen-specific T-cell responses predominate, we performed a challenge with the major house-dust mite allergen, D. pteronyssinus (atopy patch test). Copyright © 2011 Massachusetts Medical Society. All rights reserved. Clinical and histologic signs of eczema developed in Patients 1 and 2. Eczema-invading T cells were mostly Th2 cells, 7,14 a large number of which reacted to D. pteronyssinus allergen challenge in vitro after antigen presentation by autologous monocytes ( Fig. 2A, 2D , and 2E).
Table 1. Characteristics of the Three Patients with Atopic Eczema and Psoriasis and Five Additional Patients with Psoriasis and Allergic Contact Dermatitis (from Nickel).* Characteristic

Patients with Atopic Eczema and Psoriasis
Patients with Psoriasis and Allergic Contact Dermatitis
To determine whether psoriasis and eczema are caused by opposing T-cell subsets or antigenspecific T cells, we expanded testing to include eczema-inducing agents that typically elicit a Th1and Th17-cell immune response, such as nickel. On epicutaneous challenge with the hapten nickel, five additional patients with psoriasis and a known sensitization to nickel (allergic contact dermatitis) ( Table 1) had an eczema reaction (Fig. 2B ). Histologic analysis of biopsy specimens from fresh psoriasis lesions and from patch test-induced eczema, obtained at the same time, confirmed the clinical diagnosis. Whereas the cellular infiltrate in atopic eczema lesions was dominated by Th2 cells, the infiltrate in allergic contact dermatitis lesions, like the infiltrate in psoriasis lesions, was dominated by Th1 and Th17 cells (Fig. 2C) . This finding may explain why psoriasis in combination with allergic contact dermatitis is much more common than psoriasis in combination with atopic eczema. A large percentage of T cells derived from allergic contact dermatitis lesions reacted to nickel in vitro, whereas few T cells were reactive to nickel in psoriasis lesions ( Fig. 2D and 2E ).
Besides the differences in their cellular infiltrates, atopic eczema lesions and psoriasis lesions could also be distinguished according to skin colonization with microorganisms and filaggrin expression. Namely, all atopic eczema lesions, but not psoriasis lesions, were colonized with Staphylococcus aureus, as determined by smear-test culture. Furthermore, filaggrin expression, measured immunohistochemically, was higher in psoriasis lesions than in atopic eczema lesions (Fig. 1A) .
DISCUSSION
Our findings suggest that an intrinsic epithelial abnormality is not the basis of the pathogenesis of psoriasis or atopic eczema. Rather, specific T cells migrate into the skin in response to distinct antigen triggers and determine the outcome of an inflammatory skin disease -that is, atopic eczema or psoriasis. Thus, antigens differ in the skin reactions they elicit. The specific antigen exposures that lead to psoriasis are undefined.
Besides indicating antigen dependence, our findings shed light on how the local cytokine microenvironment directs cutaneous immunity. The fact that atopic eczema lesions, but not psoriasis plaques, were colonized with S. aureus confirms that Th17 and Th1 cells induce an innate immune response in the skin that is partially antagonized by Th2 cells. 8, 15 Furthermore, the lower filaggrin expression in atopic eczema lesions is consistent with the finding that Th2 cytokines inhibit expression of the filaggrin gene in vitro. 16 Formerly, topical glucocorticoids and systemic immunosuppressive drugs were the only therapies for both psoriasis and atopic eczema. An understanding of the molecular basis of both diseases has led to the development of more targeted biologic therapies. The diversity of psoriasis and atopic eczema is reflected by the responses to these targeted biologic agents.
For psoriasis, molecules inhibiting the proinflammatory molecule tumor necrosis factor α (TNF-α) are highly effective. In our study, while Patient 1 was receiving TNF-α antibodies (infliximab, which was discontinued after two injections because of a severe adverse event [temperature up to 39°C, arthritis symptoms, weakness, and vomiting] and adalimu mab), his psoriasis lesions Findings for Patients 1, 2, and 3 are shown in Panels A, B, and C, respectively. Clinical photographs are shown, as well as the clinical course, assessed over time by means of the psoriasis area-and-severity index (PASI, with scores ranging from 0 to 72 and higher scores indicating more severe disease) (blue lines) and the Scoring Atopic Dermatitis (SCORAD) index for AE (with scores ranging from 0 to 103 and higher scores indicating more severe disease) (red lines). Note that dates along the cleared, but his atopic eczema lesions at other sites were exacerbated (Fig. 1A, clinical course) . Thus, blocking a Th1-mediated and Th17-mediated immune disease with a specifically targeted agent may result in a flare of Th2-mediated disease.
Another promising therapy for psoriasis is the Th2 cytokine interleukin-4, 17 which counteracts the effects of interferon-γ and interleukin-17 on keratinocytes. 8, 15 However, since Th2 cytokines are overproduced by the cellular infiltrate of atopic eczema lesions, interleukin-4 would not be expected to ameliorate skin symptoms of atopic eczema. In fact, biologic drugs specifically inhibiting one T-cell subset appear to be ineffective for the treatment of co-occurring psoriasis and atopic eczema. Instead, our patients benefited from less specific therapy, aimed at general T-cell suppression: in Patient 1, psoriasis and atopic eczema lesions cleared after receipt of the anti-interleukin-12 p40-subunit antibody ustekinu mab, which targets Th1 and Th17 cells (Fig. 1A) . Ustekinumab is effective in treating psoriasis, 18 whereas evidence-based data regarding its effect on atopic eczema are lacking. However, since there are reports that Th1 and Th17 respond to microbial antigens (e.g., the S. aureus infecting our patients with atopic eczema) and to self-antigens released after cell damage, during the chronic phase of atopic eczema, 1,8 ustekinumab could partially improve atopic eczema lesions. Cyclosporine suppresses all T-cell subpopulations through calcineurin inhibition and was a highly effective treatment for both psoriasis and atopic eczema lesions in Patient 2 (Fig. 1B, clinical course) .
In summary, we describe the rare simultaneous occurrence of two supposedly antagonistic diseases, psoriasis and atopic eczema. Within the same patients, distinct T-cell subpopulations were found to infiltrate the same organ: predominantly Th1 and Th17 cells in psoriasis and Th2 cells in atopic eczema. On epicutaneous challenge with eczema-inducing antigens, patients with psoriasis and sensitization against these antigens do not react with an unspecific triggering of psoriasis plaques (Koebner's phenomenon), but typical eczematous lesions containing antigen-reactive T cells do develop. Our observations suggest that distinct, antigen-specific T-cell subsets determine the pathogenesis of psoriasis and atopic eczema.
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